Skip to main content

Advertisement

Table 2 Comparison of other genetic alterations between MDS patients with and without the DNMT3A mutation

From: Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

   Number and percentage of patients with the mutation (%)  
Mutation No. examined Total patients DNMT3A-mutated patients DNMT3A-wild patients P value
IDH1 468 4 (0.9) 1 (2.7) 3 (0.7) 0.281
IDH2 464 19 (4.1) 7 (18.9) 12 (2.8) < 0.001
ASXL1 459 108 (23.5) 5 (13.5) 103 (24.4) 0.160
EZH2 469 29 (6.2) 0 (0.0) 29 (6.7) 0.153
TET2 469 61 (13.0) 7 (18.9) 54 (12.5) 0.304
FLT3/ITD 465 5 (1.1) 0 (0) 5 (1.2) > 0.999
JAK2 467 4 (0.9) 0 (0.0) 4 (0.9) > 0.999
NRAS 469 25 (5.3) 2 (5.4) 23 (5.3) > 0.999
KRAS 465 8 (1.7) 1 (2.7) 7 (1.6) 0.488
PTPN11 119 1 (0.8) 0 (0) 1 (1.0) > 0.999
WT1 256 1 (0.4) 0 (0) 1 (0.4) > 0.999
MLL/PTD 447 5 (1.1) 2 (5.4) 3 (0.7) 0.057
RUNX1 462 61 (13.2) 7 (18.9) 54 (12.7) 0.308
U2AF1 469 35 (7.5) 2 (5.4) 33 (7.6) > 0.999
SRSF2 469 60 (12.8) 5 (13.5) 55 (12.7) 0.801
SF3B1 469# 48 (10.2) 11 (29.7) 37 (8.6) < 0.001
Lower-risk IPSS 249 33 (13.3) 7 (46.7) 26 (11.1) 0.001
Higher-risk IPSS 188 11 (5.9) 3 (15) 8 (4.8) 0.098
SETBP1 466 15 (3.2) 0 (0) 15 (3.5) 0.621
TP53 465 42 (9.0) 4 (10.8) 38 (8.9) 0.763
  1. Abbreviations: No. number, ITD internal tandem duplication, PTD partial tandem duplication
  2. #Four hundred and thirty-seven of them had cytogenetic data and could be assigned to the IPSS-R risk groups